Enhancing Drug Repurposing with Consensus Docking: Discovery of Novel Discoidin Domain Receptor 1 Inhibitors

Developing novel drugs is a long and difficult process, particularly in oncology, where high attrition rates make clinical trials costly and time-consuming. In response, drug repurposing emerges as an efficient alternative: existing compounds can be used effectively in new therapeutic contexts. Discoidin domain receptor 1 (DDR1), a receptor tyrosine kinase involved in tumor progression, has emerged as a promising target for solid tumor treatment. To identify novel potential DDR1 inhibitors, we applied ESSENCE-Dock, an in-house consensus docking method designed to improve hit enrichment. Using this approach, we performed virtual screening of the DrugBank database, a comprehensive collection of Food and Drug Administration-approved and investigational drugs. To ensure novelty, we performed fingerprint dissimilarity analysis against known DDR1 inhibitors from BindingDB, prioritizing structurally distinct candidates. While several known DDR1 inhibitors ranked among the top-scoring compounds, we prioritized novel, structurally distinct candidates for testing. Biochemical IC₅₀ assays validated three previously unreported DDR1 inhibitors with nanomolar potency, while molecular dynamics simulations confirmed their stable binding within the DDR1 active site. Functional cell-based assays revealed inhibition of DDR1-mediated signaling and cancer cell migration. These findings demonstrate the effectiveness of our consensus-based virtual screening approach in drug repurposing and underscore its potential to streamline oncology drug development.